BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2026)

BioXcel Therapeutics' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 105.13% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 105.13% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, down 73.01% from the prior year.
• Other Non-Current Liabilities improved to $6.7 million in Q1 2026 per BTAI's latest filing, from $1.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $21.2 million in Q1 2024 and bottomed at $1.8 million in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $2.6 million (2023), against an average of $4.6 million.
• Across the five-year window, Other Non-Current Liabilities surged 724.48% in 2024 and slumped 84.57% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $2.3 million in 2022, then dropped by 18.69% to $1.9 million in 2023, then surged by 248.19% to $6.6 million in 2024, then sank by 73.01% to $1.8 million in 2025, then surged by 275.2% to $6.7 million in 2026.
• Per Business Quant, the three latest BTAI Other Non-Current Liabilities figures stand at $6.7 million (Q1 2026), $1.8 million (Q4 2025), and $3.6 million (Q3 2025).